Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients

被引:4
|
作者
Wang, Miao [1 ,2 ]
Duan, Bao-ling [2 ]
Yuan, Yin-jin [3 ]
Su, Xia [1 ]
Zheng, Hang [1 ]
Wang, Fu-sheng [2 ]
Sun, He [1 ]
机构
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, 92 Weijin Rd, Tianjin 300072, Peoples R China
[2] North China Pharmaceut Grp Corp, New Drug Res & Dev Ctr, Natl Engn Res Ctr Microbial Med, Shijiazhuang, Hebei, Peoples R China
[3] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China
关键词
renal transplant patients; healthy subjects; population pharmacokinetics; sirolimus; cyclosporine; CLINICAL PHARMACOKINETICS; PEDIATRIC-PATIENTS; RAPAMYCIN; SAFETY; CYCLOSPORINE; VOLUNTEERS; RECIPIENTS; REJECTION; EFFICACY; ADULT;
D O I
10.5414/CP202499
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To identify the factors affecting the pharmacokinetics (PKs) of sirolimus in healthy Chinese subjects and renal transplant patients. Methods: A population PK model of sirolimus was constructed using dense data from 22 healthy volunteers and sparse data from 105 renal transplant patients. Results: The data were well described by a two-compaitment model with first-order absorption. The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively. The CL/F in renal transplant patients was 45.5% lower than that in healthy subjects. Based on the final model, CL/F decreased significantly with increasing cyclosporine (CsA) daily dose and age. A decrease of 7.3% in CL/F for every 100-mg increase in the CsA daily dose and a decrease of 34.2% in CL/F for every 20-year increase in age was observed. Moreover, V2/F increased significantly with increasing serum creatinine in our study. However, the range of serum creatinine concentration and the interindividual variability for V2/F are large. Conclusion: This is the first study to characterize the population PKs of sirolimus using a two-compartment model in healthy Chinese subjects and renal transplant patients. A decrease of 7.3% in the sirolimus CL/F for every 100-mg increase in the CsA daily dose and a decrease of 34.2% in the sirolimus CL/F for every 20-year increase in age was observed, which allowed us to better optimize sirolimus dosing regimens in Chinese renal transplant patients.
引用
收藏
页码:433 / 441
页数:9
相关论文
共 50 条
  • [1] Population Pharmacokinetics of Sirolimus in Healthy Chinese Subjects
    Peng, M.
    Zhao, G.
    Li, X.
    Chen, M.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 80 (02) : 291 - 297
  • [2] POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF SIROLIMUS AND ITS IMPACT ON CHOLESTEROL IN CHINESE ADULT RENAL TRANSPLANT PATIENTS
    Jiao, Z.
    Shi, X.
    Li, Z.
    Zhong, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S85 - S86
  • [3] VALIDATION OF A POPULATION PHARMACOKINETIC MODEL TO INDIVIDUALISE THE SIROLIMUS DOSAGE IN RENAL TRANSPLANT PATIENTS
    Valdivieso, J. Gonzalez
    Agrad, F. Z.
    Oltra, B. Porta
    Rodriguez, M.
    Calvo, R.
    Jimenez Torres, N. V.
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 147 - 147
  • [4] Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients
    Jiao, Zheng
    Shi, Xiao-jin
    Li, Zhong-dong
    Zhong, Ming-kang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) : 47 - 60
  • [5] Population Pharmacokinetic Analysis of Valsartan in Healthy Chinese Subjects
    Yang, Haiyun
    Gao, Ruomei
    Ji, Xingfang
    Wang, Zhipeng
    Qiu, Wen
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (03): : 249 - 256
  • [6] A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients
    Lu, Yan-xia
    Su, Qing-hong
    Wu, Ke-hua
    Ren, Yu-peng
    Li, Liang
    Zhou, Tian-yan
    Lu, Wei
    ACTA PHARMACOLOGICA SINICA, 2015, 36 (02) : 281 - 288
  • [7] A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients
    Yan-xia Lu
    Qing-hong Su
    Ke-hua Wu
    Yu-peng Ren
    Liang Li
    Tian-yan Zhou
    Wei Lu
    Acta Pharmacologica Sinica, 2015, 36 : 281 - 288
  • [8] Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients
    Guan, Xiao-feng
    Li, Dai-yang
    Yin, Wen-jun
    Ding, Jun-jie
    Zhou, Ling-yun
    Wang, Jiang-lin
    Ma, Rong-Rong
    Zuo, Xiao-cong
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (01) : 55 - 62
  • [9] Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients
    Chen, Bing
    Zhang, WeiXia
    Gu, ZhiDong
    Li, Juan
    Zhang, YuXin
    Cai, WeiMin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (06) : 601 - 612
  • [10] Population Pharmacokinetic Analysis of Mizoribine in Chinese Renal Transplant Recipients
    Liu, L.
    Ren, B.
    Zhang, H.
    Li, J.
    Fu, Q.
    Jiang, J.
    Deng, S.
    Qiu, J.
    Chen, G.
    Fei, J.
    Chen, L.
    Wang, C.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (08) : 2392 - 2397